Lagha A.,Hopital Abderrahmane Mami |
Chraiet N.,Institute Salah Azaiez |
Labidi S.,Hopital Abderrahmane Mami |
Krimi S.,Hopital Abderrahmane Mami |
And 3 more authors.
Bulletin du Cancer | Year: 2013
The use of regimens with adjuvant taxanes reduces the risk of recurrence and improves survival in patients with node-positive breast cancer, but the use of taxanes in node-negative breast cancer is still to be defined. The aim of this study is to evaluate the role of taxanes in high-risk nodenegative breast cancer. Two categories of studies were reviewed: studies that evaluated both nodepositive and node-negative breast cancers, and studies that included only high-risk node-negative breast cancers. Three phase-III studies that evaluated both negative and positive nodes did not show any benefit of the use of taxanes according to the node-negative subgroup analyses, versus two studies (European Cooperative Trial in Operable Breast Cancer [ECTO] et Grupo Espãnol de Investigación del Cáncer de Mama [GEICAM]) that showed a significant difference in disease-free survival. In view of these studies, the role of taxanes in nodenegative breast cancer is still controversial and the results of the ongoing trials may respond to this subject. Source
Afrit M.,Hopital Abderrahmane Mami |
Yahyaoui Y.,Hopital Abderrahmane Mami |
Bouzouita A.,Hopital Charles Nicolle |
Hantous S.,Tunis el Manar University |
And 6 more authors.
Presse Medicale | Year: 2015
Aims: To analyze the medical literature concerning the results of the international randomized muticentric trials concerning therapeutic innovations, mainly targeted therapies in locally advanced and or metastatic renal cell cancer and to evaluate the benefit of these TT. Methods: We performed a review of publications that concerned this topic published from 2000 to 2014. Results: They concerned the large randomized trials have showed a benefit of the targeted therapies in the treatment of clear cell carcinomas in terms of progression-free survival. Conclusion: Advances in molecular biology have allowed the development of these targeted therapies that have all proved their role in the treatment of metastatic renal cell carcinoma. © 2014 Elsevier Masson SAS. Source